Latest news with #MichaelRyskin
Yahoo
22-04-2025
- Business
- Yahoo
Align Technology price target lowered to $185 from $200 at BofA
BofA analyst Michael Ryskin lowered the firm's price target on Align Technology (ALGN) to $185 from $200 and keeps an Underperform rating on the shares. Heading into Q1 earnings, the firm trimmed volume expectations for Align given persistent end-market weakness, but took average selling prices higher to reflect reduced foreign exchange headwinds. Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on ALGN: Disclaimer & DisclosureReport an Issue Align Technology price target lowered to $249 from $272 at Morgan Stanley GOOGL, ON, ALGN: Morningstar (MORN) Names Top-Rated Stocks That Are Undervalued Align Technology announces commercial availability of Invisalign with mandibula Align Technology price target lowered to $250 from $295 at Mizuho Positive Outlook for Align Technology Amidst Stabilizing Market Share and Competitive Pressures
Yahoo
15-04-2025
- Business
- Yahoo
Quest Diagnostics price target raised to $198 from $190 at BofA
BofA analyst Michael Ryskin raised the firm's price target on Quest Diagnostics (DGX) to $198 from $190 and keeps a Buy rating on the shares. Sentiment for Life Sciences and Diagnostic Tools and Contract Research Organizations is 'particularly negative' heading into earnings given that these companies 'sit at the intersection of a number of policy changes from the Trump Administration,' including headwinds from NIH budget cuts and global tariffs, as well as broader macro concerns, especially around China, the analyst tells investors in a preview for the group. Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on DGX: Disclaimer & DisclosureReport an Issue Quest Diagnostics launches AD-Detect blood test for Alzheimer's confirmation Quest Diagnostics price target raised to $189 from $178 at Mizuho Quest Diagnostics initiated with a Buy at Redburn Atlantic Quest Diagnostics: Steady Growth and Strategic Advancements Justify Buy Rating Quest Diagnostics: Resilient Investment with Strategic Growth Initiatives and Strong Financials
